Funding news · Sep 14, 2026
Amra Medical Secures Funding from HealthCap
Amra Medical Secures Funding from HealthCap
Amra Medical, a Swedish health informatics company based in Linköping, has raised an undisclosed round of funding. The round is backed by HealthCap, which participated as an investor. The funding was recorded on September 14, 2026, and the round type was not disclosed.
What Amra Medical Does
Amra Medical operates at the intersection of medical imaging and health informatics. The company turns standard MRI scans into automated, standardized biomarkers for muscle and fat composition. Its patented, MRI-based analysis methods are used by research teams and clinicians worldwide.
The company's digital platform includes two core products:
- AMRA Researcher — aimed at pharmaceutical drug development and clinical research, optimizing trial design and endpoints and supporting metabolic and neuromuscular research.
- AMRA Profiler — part of the same digital platform serving research and clinical workflows.
Beyond its research-facing platform, Amra Medical offers clinical services that extend the same imaging insights to patient care:
- AMRA BCP Scan
- MAsS Scan
Together, these products and services position Amra Medical as a provider of standardized body composition biomarkers across both drug development and clinical care settings.
Funding Details
| Item | Detail |
|---|---|
| Company | Amra Medical |
| Headquarters | Linköping, Sweden |
| Round type | Undisclosed |
| Funding amount | Not disclosed |
| Funding date | September 14, 2026 |
| Investor | HealthCap |
| Lead investor | Not disclosed |
HealthCap is the sole investor named in the funding. No lead investor was specified, and no funding amount was disclosed.
Why This Matters for the Market
Amra Medical sits in a category where imaging data is converted into quantitative, standardized biomarkers — a capability with direct relevance to pharmaceutical sponsors designing metabolic and neuromuscular trials. Standardized endpoints can reduce variability in trial data, which is a persistent challenge in drug development.
The company's dual positioning is notable: it serves research organizations through its digital platform while also offering clinical services that bring the same imaging insights into patient care. That combination gives Amra Medical exposure to both the drug development pipeline and the clinical delivery market.
With patented MRI-based analysis methods and a global base of research teams and clinicians using its tools, Amra Medical has built a defensible technical position in body composition analysis.
Acquisition Angle
For acquirers in health informatics, medical imaging, or clinical research technology, Amra Medical represents a company with:
- A standardized, automated biomarker platform built on patented MRI analysis methods
- Established products (AMRA Researcher, AMRA Profiler) serving pharmaceutical drug development and clinical research
- Clinical service lines (AMRA BCP Scan, MAsS Scan) that extend into patient care
- A global user base of research teams and clinicians
The involvement of HealthCap, a life sciences-focused investor, signals continued institutional interest in the company's research and clinical applications. The undisclosed nature of the round means financial terms are not public, but the participation of a specialist healthcare investor is a relevant signal for parties tracking the company's trajectory.
Summary
Amra Medical, based in Linköping, Sweden, has raised an undisclosed round dated September 14, 2026, with HealthCap as an investor. The company converts standard MRI scans into automated, standardized biomarkers for muscle and fat composition, serving pharmaceutical drug development, clinical research, and patient care through its digital platform and clinical services. No funding amount or lead investor was disclosed.